Strona 1 od 642 wyniki
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2009/004301, filed Jul. 31, 2009, which claims benefit of Korean Patent Applications 10-2008-0075659, filed Aug. 1, 2008, and 10-2009-0032463, filed
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2010/008944, filed Dec. 14, 2010, which claims benefit of Korean Patent Application No. 10-2010-0004901, filed Jan. 19, 2010.
FIELD OF THE
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of PCT International Application PCT/KR2011/010161, filed Dec. 27, 2011, which claims priority from Korean Patent Application 10-2011-0010585, filed Feb. 7, 2011.
TECHNICAL FIELD
The
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2009/007905, filed Dec. 29, 2009, which claims benefit of Korean Patent Application 10-2009-0022937, filed Mar. 18, 2009.
TECHNICAL FIELD
The
FIELD OF THE INVENTION
The invention provides a water extract of Yan-Sheng-Yin (YSY), a Chinese natural dietary supplement for health promotion, comprised entirely of natural foods and a preparation comprising the same. The invention also provides a method for treatment and/or prevention of
CROSS REFERENCE TO PRIOR APPLICATIONS
This application claims the benefit of PCT International Application No.
PCT/MX2005/000058, filed Jul. 18, 2005, which claims priority from Mexican Patent Application No. PA/a/2004/0010692, filed Oct. 28, 2004, the entire disclosures of which are incorporated by
FIELD OF THE INVENTION
The present invention relates to medicine technology, and more specifically, it relates to a new use of HMG-CoA reductase inhibitor (statins compound) locally used for prevention and treatment of diabetes, obesity, hypertension, hyperlipidemia, artheroslerosis, cardiovascular
This is a U.S. National Phase entry based on PCT/CN2013/001429 filed Nov. 22, 2013, which respectively claiming priority to Chinese patent application 20120512630.8 filed Nov. 23, 2012 and Chinese patent application 201310426327.0 filed Sep. 18, 2013.
FIELD OF THE INVENTION
The present invention
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national phase, pursuant to 35 U.S.C. .sctn.371, of PCT international application Ser. No. PCT/KR2011/003007, filed Apr. 25, 2011, designation the United States and published in Korean on Dec. 15, 2011 as publication WO2011/155705.
BACKGROUND INFORMATION
An estimated 1.1 billion adults worldwide are overweight or obese, one hundred thirty million of whom are adults in the United States. See, Haslam, D., Sattar, N., & Lean, M. (2006). Obesity--time to wake up. Bmj, 333(7569), 640-642; Flegal, K. M., Carroll, M. D., Ogden,
The present invention relates to pyrrolidinone derivatives of the formula I
##STR00001##
in which R.sup.1a, R.sup.1b, R.sup.1c, R.sup.2a, R.sup.2b, R.sup.2c, X, Y.sup.1 and Y.sup.2 are defined as indicated below. The pyrrolidinone derivatives I are GPR119 modulators and useful for the prevention
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims priority benefit to EP Application No. 17305189.7, filed Feb. 21, 2017, the disclosure of which is herein incorporated by reference in its entirety.
DETAILED DESCRIPTION
The present disclosure relates to compounds of formula
The present invention relates to isoindolinone compounds of the formula I
##STR00001## in which A, X, R1b, R1c, R2a, R2b, R2c, R3, R4, R30, Y and Z are defined as indicated below. The isoindolinone compounds I are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity,
BACKGROUND INFORMATION
An estimated 1.1 billion adults worldwide are overweight or obese, one hundred thirty million of whom are adults in the United States. See, Haslam, D., Sattar, N., & Lean, M. (2006). Obesity--time to wake up. Bmj, 333(7569) 640-642; Flegal, K. M., Carroll, M. D., Ogden, C.
FIELD OF THE INVENTION
The present invention relates to inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase Type I (11.beta.-HSD-1 or HSD-1), and methods of treatment using such compounds. The compounds are useful for the treatment of diabetes, such as non-insulin dependent type 2 diabetes